fax: 510-642-0535
Steatohepatitis/Metabolic Liver Disease
Specific bile acids inhibit hepatic fatty acid uptake in mice†
Article first published online: 4 OCT 2012
DOI: 10.1002/hep.25797
Copyright © 2012 American Association for the Study of Liver Diseases
Additional Information
How to Cite
Nie, B., Park, H. M., Kazantzis, M., Lin, M., Henkin, A., Ng, S., Song, S., Chen, Y., Tran, H., Lai, R., Her, C., Maher, J. J., Forman, B. M. and Stahl, A. (2012), Specific bile acids inhibit hepatic fatty acid uptake in mice. Hepatology, 56: 1300–1310. doi: 10.1002/hep.25797
- †
Potential conflict of interest: Nothing to report.
- ‡
fax: 510-642-0535
Publication History
- Issue published online: 4 OCT 2012
- Article first published online: 4 OCT 2012
- Accepted manuscript online: 24 APR 2012 12:17PM EST
- Manuscript Accepted: 16 APR 2012
- Manuscript Received: 8 DEC 2011
Funded by
- National Institute of Diabetes and Digestive and Kidney Diseases. Grant Number: R56DK066336, DK089202, and R01DK066336
- University of California San Francisco Liver Center. Grant Number: P30 DK026743
Abstract
Bile acids are known to play important roles as detergents in the absorption of hydrophobic nutrients and as signaling molecules in the regulation of metabolism. We tested the novel hypothesis that naturally occurring bile acids interfere with protein-mediated hepatic long chain free fatty acid (LCFA) uptake. To this end, stable cell lines expressing fatty acid transporters as well as primary hepatocytes from mouse and human livers were incubated with primary and secondary bile acids to determine their effects on LCFA uptake rates. We identified ursodeoxycholic acid (UDCA) and deoxycholic acid (DCA) as the two most potent inhibitors of the liver-specific fatty acid transport protein 5 (FATP5). Both UDCA and DCA were able to inhibit LCFA uptake by primary hepatocytes in a FATP5-dependent manner. Subsequently, mice were treated with these secondary bile acids in vivo to assess their ability to inhibit diet-induced hepatic triglyceride accumulation. Administration of DCA in vivo via injection or as part of a high-fat diet significantly inhibited hepatic fatty acid uptake and reduced liver triglycerides by more than 50%. Conclusion: The data demonstrate a novel role for specific bile acids, and the secondary bile acid DCA in particular, in the regulation of hepatic LCFA uptake. The results illuminate a previously unappreciated means by which specific bile acids, such as UDCA and DCA, can impact hepatic triglyceride metabolism and may lead to novel approaches to combat obesity-associated fatty liver disease. (HEPATOLOGY 2012)

1527-3350/asset/olbannerleft.gif?v=1&s=4b2409f9534ed500d3c8da1940a23842e2b9932d)
1527-3350/asset/olbannerright.gif?v=1&s=141b9a8485298533c3e2016e937b0404f7d933e1)
